Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 7, Number 1—February 2001
Research

Active Bacterial Core Surveillance of the Emerging Infections Program Network

Anne Schuchat*Comments to Author , Tami Hilger*, Elizabeth Zell*, Monica M. Farley†, Arthur L. Reingold‡, Lee H. Harrison§, Lewis Lefkowitz¶, Richard Danila**, Karen Stefonek††, Nancy Barrett‡‡, Dale Morse§§, Robert W. Pinner*, and for the Active Bacterial Core Surveillance Team of the Emerging Infections Program Network
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Georgia Emerging Infection Program (Georgia Department of Human Resources, Division of Public Health, Emory University School of Medicine, and the Atlanta Veterans Administration Medical Center) Atlanta, Georgia, USA; ‡California Department of Health Services and UC Berkeley School of Public Health, Berkeley, California, USA; §Maryland Department of Health and Mental Hygiene and Johns Hopkins University School of Public Health, Baltimore, Maryland, USA; ¶Tennessee Department of Health and Vanderbilt University Medical Center, Nashville, Tennessee, USA; **Minnesota Department of Health, St. Paul, Minnesota, USA; ††Oregon Department of Human Resources, Portland, Oregon, USA; ‡‡Connecticut Department of Public Health, Hartford, Connecticut, USA; §§New York State Department of Health, Albany, New York, USA

Main Article

Table 3

Population-based risk factors for invasive disease, identified by Active Bacterial Core surveillance

Factors associated with increased risk by
Pathogen Age group, other criteria multivariate analysis References
Streptococcus pneumoniae <5 years old Child-care attendance, underlying conditions, lack of breast-feeding, household crowding (29)
18-64 years old, not immunocompromised Active or passive smoke exposure, black race, chronic diseases, household contact with child in day care (30)
Neisseria meningitidis All ages Active or passive smoke exposure, underlying conditions, steroid use, attendance at new school (31)
Group B Streptococcus <7 days old Black race, low birth weight, maternal age <20 years CDC, 
unpub. data

Main Article

References
  1. Lederberg  J, Shope  RE, Oaks  SCJ. Emerging infections: microbial threats to health in the United States. Washington: National Academy Press; 1992.
  2. Centers for Disease Control and Prevention. Defining the public health impact of drug-resistant Streptococcus pneumoniae: report of a working group. MMWR Morb Mortal Wkly Rep. 1996;45(No.RR-1):1–14.PubMedGoogle Scholar
  3. Klugman  KP. Pneumococcal resistance to antibiotics. Clin Microbiol Rev. 1990;3:171–96.PubMedGoogle Scholar
  4. Centers for Disease Control and Prevention. Geographic variation in penicillin resistance in Streptococcus pneumoniae--selected sites, United States, 1997. MMWR Morb Mortal Wkly Rep. 1999;48:656–61.PubMedGoogle Scholar
  5. Charles  D, Larsen  B. Streptococcal puerperal sepsis and obstetric infections: a historical perspective. Rev Infect Dis. 1986;8:411–22.PubMedGoogle Scholar
  6. Schwartz  B, Facklam  RR, Breiman  RF. Changing epidemiology of group A streptococcal infection in the USA. Lancet. 1990;336:1167–71. DOIPubMedGoogle Scholar
  7. Freedman  RA, Ingram  DL, Gross  I, Ehrenkranz  PA, Warshaw  JB, Baltimore  RS. A half century of neonatal sepsis at Yale, 1928 to 1978. Am J Dis Child. 1981;135:140–4.PubMedGoogle Scholar
  8. McCracken  GH. Group B streptococci: the new challenge in neonatal infections. J Pediatr. 1973;82:703–6. DOIPubMedGoogle Scholar
  9. Centers for Disease Control and Prevention. Recommendations for use of Haemophilus influenzae b conjugate vaccines and a combined diphtheria, tetanus, pertussis and Haemophilus b vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1993;42(RR-13):1–15.PubMedGoogle Scholar
  10. Schuchat  A, Robinson  K, Wenger  JD, Harrison  LH, Farley  M, Reingold  AL, Bacterial meningitis in the United States in 1995. N Engl J Med. 1997;337:970–6. DOIPubMedGoogle Scholar
  11. Centers for Disease Control and Prevention. Addressing emerging infectious disease threats: a prevention strategy for the United States. Atlanta: Centers for Disease Control and Prevention; 1994.
  12. Centers for Disease Control and Prevention. Preventing emerging infectious diseases: a strategy for the 21st century. Atlanta: Centers for Disease Control and Prevention; 1998.
  13. Schuchat  A, Whitney  C, Zangwill  K. Prevention of perinatal group B streptococcal disease: a public health perspective. MMWR Morb Mortal Wkly Rep. 1996;45(No. RR-7):1–24.PubMedGoogle Scholar
  14. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1997;46(RR-8):1–24.PubMedGoogle Scholar
  15. Wenger  JD, Pierce  R, Deaver  K, Plikaytis  BD, Facklam  RR, Broome  CV. Efficacy of Haemophilus influenzae type b polysaccharide-diptheria toxoid conjugate vaccine in US children aged 18-59 months. Lancet. 1991;338:395–8.PubMedGoogle Scholar
  16. Schuchat  A, Deaver  K, Wenger  JD, Plikaytis  BD, Mascola  L, Pinner  RW, Role of foods in sporadic listeriosis. I: case-control study of dietary risk factors. JAMA. 1992;267:2041–5. DOIPubMedGoogle Scholar
  17. Pinner  RW, Schuchat  A, Swaminathan  B, Hayes  PS, Deaver  KA, Weaver  RE, Role of foods in sporadic listeriosis. II: microbiologic and epidemiologic investigation. JAMA. 1992;267:2046–50. DOIPubMedGoogle Scholar
  18. Mohle-Boetani  J, Schuchat  A, Plikaytis  BD, Smith  D, Broome  CV. Comparison of prevention strategies for neonatal group B streptococcal infection: a population-based economic analysis. JAMA. 1993;270:1442–8. DOIPubMedGoogle Scholar
  19. Centers for Disease Control and Prevention. The Foodborne Diseases Active Surveillance Network, 1996. MMWR Morb Mortal Wkly Rep. 1997;46:258–61.PubMedGoogle Scholar
  20. Perkins  BA, Flood  JM, Danila  R, Holman  RC, Reingold  AL, Klug  LA, Unexplained deaths due to possibly infectious causes in the United States: defining the problem and designing surveillance and laboratory approaches. Emerg Infect Dis. 1996;2:47–53. DOIPubMedGoogle Scholar
  21. Zangwill  KM, Schuchat  A, Wenger  JD. Group B streptococcal disease in the United States, 1990: report from a multistate active surveillance system. MMWR Morb Mortal Wkly Rep. 1992;41(SS-6):25–32.PubMedGoogle Scholar
  22. Schrag  S, Zywicki  S, Farley  MM, Reingold  AL, Harrison  LH, Lefkowitz  LB, Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis, 1993-1998. N Engl J Med. 2000;342:15–20. DOIPubMedGoogle Scholar
  23. Chin  AE, Hedberg  K, Cieslak  PR, Cassidy  M, Stefonek  KR, Fleming  DW. Tracking drug-resistant Streptococcus pneumoniae in Oregon: an alternative surveillance method. Emerg Infect Dis. 1999; 5.PubMedGoogle Scholar
  24. Beall  B, Facklam  R, Thompson  T. Sequencing the emm-specific PCR products for routine and accurate typing of group A streptococci. J Clin Microbiol. 1996;34:953–8.PubMedGoogle Scholar
  25. Harrison  LH, Dwyer  DM, Johnson  JA. Emergence of serotype V group B streptococcal infection among infants and adults. J Infect Dis. 1995;171:513.PubMedGoogle Scholar
  26. Blumberg  HM, Stephens  DS, Modansky  M, Erwin  M, Elliott  J, Facklam  R, Invasive group B streptococcal disease: the emergence of serotype V. J Infect Dis. 1996;173:365–73.PubMedGoogle Scholar
  27. Swartley  JS, Marfin  AA, Edupuganti  S, Liu  LJ, Cieslak  P, Perkins  B, Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci U S A. 1997;94:271–6. DOIPubMedGoogle Scholar
  28. Gherardi  G, Whitney  C, Facklam  R, Beall  B. Major related sets of antibiotic-resistant pneumococci in the United States as determined by pulsed-field gel electrophoresis and pbp1a-pbp2b-pbp2x-dhf restriction profiles. J Infect Dis. 2000;181:216–29. DOIPubMedGoogle Scholar
  29. Levine  OS, Farley  MM, Harrison  LH, Lefkowitz  L, McGeer  A, Schwartz  B. Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. Pediatrics. 1999;103:e28. DOIPubMedGoogle Scholar
  30. Nuorti  JP, Butler  JC, Farley  MM, Harrison  LH, McGeer  A, Kolczak  MS, Cigarette smoking and invasive pneumococcal disease. N Engl J Med. 2000;342:681–9. DOIPubMedGoogle Scholar
  31. Fischer  M, Harrison  L, Farley  M, Lefkowitz  L, McGeer  A, Schuchat  A, Risk factors for sporadic meningococcal disease in North America. Philadelphia: Infectious Diseases Society of America; 2000.
  32. Lingappa  J, Zell  E, Rosenstein  N, Schuchat  A, Perkins  BA. Active Bacterial Core surveillance. Impact of vaccination strategies using meningococcal conjugate vaccines in the United States. Philadelphia: Infectious Disease Society of America; 1999.
  33. Feikin  DR, Schuchat  A, Kolczak  M, Barrett  NL, Harrison  LH, Lefkowitz  L, Mortality for invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health. 2000;90:223–9. DOIPubMedGoogle Scholar
  34. Centers for Disease Control and Prevention. Laboratory practices for prenatal group B streptococcal screening and reporting--Connecticut, Georgia, and Minnesota, 1997-1998. MMWR Morb Mortal Wkly Rep. 1999;48:426–8.PubMedGoogle Scholar
  35. Centers for Disease Control and Prevention. Laboratory capacity to detect antimicrobial resistance. MMWR Morb Mortal Wkly Rep. 2000;48:1167–71.PubMedGoogle Scholar
  36. Centers for Disease Control and Prevention. Surveillance for Creutzfeldt-Jakob Disease--United States. MMWR Morb Mortal Wkly Rep. 1996;45:665–8.PubMedGoogle Scholar
  37. Centers for Disease Control and Prevention. Intussusception among recipients of rotavirus vaccine--United States, 1998-1999. MMWR Morb Mortal Wkly Rep. 1999;48:577–81.PubMedGoogle Scholar
  38. Centers for Disease Control and Prevention. Adoption of hospital policies for prevention of perinatal group B streptococcal disease--United States, 1997. MMWR Morb Mortal Wkly Rep. 1998;47:665–70.PubMedGoogle Scholar
  39. Factor  SH, Whitney  CG, Zywicki  S, Schuchat  A. the ABC Surveillance Team. Effects of hospital policies on the 1996 Group B streptococcal consensus guidelines. Obstet Gynecol. 2000;95:377–82. DOIPubMedGoogle Scholar
  40. Roome  A, Carley  K, Melchreit  R, Foye  G, Hadler  J. Testing pregnant women for HIV. A survey of obstetricians and review of patient prenatal/obstetric medical records--Connecticut 1996-1997. Conn Med. 1999;63:541.
  41. Lynfield  R, Rubin  M, White  K, Schuchat  A, Moore  K, Osterholm  M, Prenatal HIV screening practices in Minnesota. Philadelphia: Infectious Diseases Society of America; 1999.
  42. Adams  WG, Deaver  KA, Cochi  SL, Plikaytis  BD, Zell  ER, Broome  CV, Decline of childhood Haemophilus influenzae type b disease in the Hib vaccine era. JAMA. 1993;269:221–6. DOIPubMedGoogle Scholar

Main Article

Page created: March 16, 2011
Page updated: March 16, 2011
Page reviewed: March 16, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external